The Effect of Folinic Acid on Methylenetetrahydrofolate Reductase Polymorphisms in Methotrexate-Treated Allogeneic Hematopoietic Stem Cell Transplants

Slides:

Advertisements

Similar presentations

Evidence of B Cell Immune Responses to Acute Lymphoblastic Leukemia in Murine Allogeneic Hematopoietic Stem Cell Transplantation Recipients Treated with.

Advertisements

Hematopoietic Stem Cell Transplantation in Australia and New Zealand,

Adverse Clinical Consequences of Hyperglycemia from Total Parenteral Nutrition Exposure during Hematopoietic Stem Cell Transplantation Patricia M. Sheean,

Extramedullary Relapse of Acute Leukemia after Haploidentical Hematopoietic Stem Cell Transplantation: Incidence, Risk Factors, Treatment, and Clinical.

Sirolimus in Combination with Cyclosporine or Tacrolimus Plus Methotrexate for Prevention of Graft-versus-Host Disease following Hematopoietic Cell Transplantation.

Norovirus Infection in Pediatric Hematopoietic Stem Cell Transplantation Recipients: Incidence, Risk Factors, and Outcome Joseph Delano F. Robles, Daniel.

Relative Survival of Long-Term Hematopoietic Cell Transplant Recipients Approaches General Population Rates Ian Nivison-Smith, Judy M. Simpson, Anthony.

Michael A. Pulsipher, Christina Peters, Ching-Hon Pui

How to Treat MDS without Stem Cell Transplantation

The Effect of Statin Use at the Time of Autologous Transplant on Response and Survival in Multiple Myeloma Mehdi Hamadani, Erinn Hade, Don M. Benson,

Increased Levels of Tumor Necrosis Factor α Are Associated with an Increased Risk of Cytomegalovirus Infection after Allogeneic Hematopoietic Stem Cell.

Allogeneic Hematopoietic Cell Transplantation May Alleviate the Negative Prognostic Impact of Monosomal and Complex Karyotypes on Patients with Acute.

The Outcome of Sibling and Unrelated Donor Allogeneic Stem Cell Transplantation in Adult Patients with Acute Myeloid Leukemia in First Remission Who Were.

Peter Hurley, Suma Konety, Qing Cao, Daniel Weisdorf, Anne Blaes

Influence of Stem Cell Source on Outcomes of Allogeneic Reduced-Intensity Conditioning Therapy Transplants Using Haploidentical Related Donors Kenneth.

Infusion of Ex Vivo Expanded Cord Blood Progenitor Cells Is Associated with Reduced Hospital Days and Utilization of Opiate Infusion and Total Parenteral.

The Prognostic Value of YKL-40 Concentrations in Nonmyeloablative Conditioning Allogeneic Hematopoietic Cell Transplantation Anne Mette Mørup, Brian.

Outcome of Respiratory Syncytial Virus Lower Respiratory Tract Disease in Hematopoietic Cell Transplant Recipients Receiving Aerosolized Ribavirin: Significance.

Allogeneic Stem Cell Transplantation in Congenital Hemoglobinopathies Using a Tailored Busulfan-Based Conditioning Regimen: Single-Center Experience

Adverse Clinical Consequences of Hyperglycemia from Total Parenteral Nutrition Exposure during Hematopoietic Stem Cell Transplantation Patricia M. Sheean,

Cytogenetic Evolution in Myeloid Neoplasms at Relapse after Allogeneic Hematopoietic Cell Transplantation: Association with Previous Chemotherapy and.

Impact of Polymorphic Variations of Gemcitabine Metabolism, DNA Damage Repair, and Drug-Resistance Genes on the Effect of High-Dose Chemotherapy for Relapsed.

Albuminuria in Hematopoietic Cell Transplantation Patients: Prevalence, Clinical Associations, and Impact on Survival Sangeeta R. Hingorani, Kristy Seidel,

Sabina Kersting, Leo F. Verdonck

Vascular Endothelial Growth Factor and Activin-A Serum Levels Following Allogeneic Hematopoietic Stem Cell Transplantation David Nachbaur, Petra Schumacher,

A Genetic Modifier of the Gut Microbiome Influences the Risk of Graft-versus-Host Disease and Bacteremia After Hematopoietic Stem Cell Transplantation

Carbon Monoxide Diffusion Capacity: How Low Can You Go for Hematopoietic Cell Transplantation Eligibility? Jason W. Chien, Keith M. Sullivan Biology.

Betty T. Tran, Abigail Halperin, Jason W. Chien

Autologous Is Superior to Allogeneic Hematopoietic Cell Transplantation for Acute Promyelocytic Leukemia in Second Complete Remission Jennifer L. Holter.

Donor-to-Recipient ABO Mismatch Does Not Impact Outcomes of Allogeneic Hematopoietic Cell Transplantation Regardless of Graft Source Sharat Damodar,

Incidence Rate of Fluoroquinolone-Resistant Gram-Negative Rod Bacteremia among Allogeneic Hematopoietic Cell Transplantation Patients during an Era of.

Graft Transit Time Has No Effect on Outcome of Unrelated Donor Hematopoietic Cell Transplants Performed in Australia and New Zealand: A Study from the.

Christopher C. Dvorak, Rajni Agarwal, Gary V. Dahl, John J

High Rate of Long Term Complete Remission for Patients with Chronic Lymphocytic Leukemia (CLL) Who Relapse after Allogeneic Stem Cell Transplantation.

New Light Chain Amyloid Response Criteria Help Risk Stratification of Patients by Day 100 after Autologous Hematopoietic Cell Transplantation Anita D'Souza,

Paul Szabolcs, Donna Niedzwiecki

Risk Factors and Outcome of Chronic Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation—Results from a Single-Center Observational Study

Time to Insurance Approval in Private and Public Payers Does Not Influence Survival in Patients Who Undergo Hematopoietic Cell Transplantation Vijaya.

Follicular Lymphoma: Prognostic Factors, Conventional Therapies, and Hematopoietic Cell Transplantation Laurie H. Sehn, Timothy S. Fenske, Ginna G. Laport

Observation-Based Early Warning Scores to Detect Impending Critical Illness Predict In- Hospital and Overall Survival in Patients Undergoing Allogeneic.

Total Marrow Lymphoid Irradiation/Fludarabine/ Melphalan Conditioning for Allogeneic Hematopoietic Cell Transplantation Lindsay G. Jensen, Tracey Stiller,

John Kuruvilla, John D. Shepherd, Heather J. Sutherland, Thomas J

Epidemiology, Management, and Outcome of Invasive Fungal Disease in Patients Undergoing Hematopoietic Stem Cell Transplantation in China: A Multicenter.

Long-Term Outcomes of Critically Ill Adult Allogeneic Hematopoietic Stem Cell Recipients Prakash Vishnu, Udit Roy, Pramod Guru, Colleen Thomas, Candido.

Folinic Acid Supplementation in Higher Doses is Associated with Graft Rejection in Pediatric Hematopoietic Stem Cell Transplantation Henric Lindqvist,

Transplantation Conditioning Regimens and Outcomes after Allogeneic Hematopoietic Cell Transplantation in Children and Adolescents with Acute Lymphoblastic.

Is There a Role for Autologous Stem Cell Transplantation for Patients with Acute Myelogenous Leukemia? A Retrospective Analysis Nicolas Novitzky, Valda.

Iron Overload Manifesting as Apparent Exacerbation of Hepatic Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation Rammurti.

Sabina Kersting, Ronald J. Hené, Hein A. Koomans, Leo F. Verdonck

Effect of Body Mass Index on Mortality of Patients with Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation Willis H. Navarro, Fausto R.

Clinical Significance of Serum Hepcidin Levels on Early Infectious Complications in Allogeneic Hematopoietic Stem Cell Transplantation Junya Kanda, Chisaki.

Shigeo Fuji, Hermann Einsele, Bipin N. Savani, Markus Kapp

Impact of Donor and Recipient Sex and Parity on Outcomes of HLA-Identical Sibling Allogeneic Hematopoietic Stem Cell Transplantation Alison W. Loren,

Allogeneic Stem Cell Transplantation for Aplastic Anemia

Clinical Endpoints in Allogeneic Hematopoietic Stem Cell Transplantation Studies: The Cost of Freedom Haesook T. Kim, Philippe Armand Biology of Blood.

Equivalent Survival for Sibling and Unrelated Donor Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia John Moore, Ian Nivison-Smith,

What is quality in a transplant program?

Central Nervous System Complications after Allogeneic Hematopoietic Stem Cell Transplantation: Incidence, Manifestations, and Clinical Significance Deborah.

Nonmyeloablative Stem Cell Transplantation for Myelodysplastic Syndrome or Acute Myeloid Leukemia in Patients 60 Years or Older Vikas Gupta, Andrew Daly,

Donor Cell Leukemia: A Review

Young Female Donors Do Not Increase the Risk of Graft-versus-Host Disease or Impact Overall Outcomes in Pediatric HLA-Matched Sibling Hematopoietic Stem.

Mammen Chandy Biology of Blood and Marrow Transplantation

Reduced Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation: Current Perspectives Brenda M. Sandmaier, Stephen Mackinnon, Richard.

Impact of Pretransplantation Indices in Hematopoietic Stem Cell Transplantation: Knowledge of Center-Specific Outcome Data Is Pivotal before Making Index-Based.

Analysis of Donor and Recipient ABO Incompatibility and Antibody-Associated Complications after Allogeneic Stem Cell Transplantation with Reduced-Intensity.

Pre-Transplant Comorbidity As an Outcome Predictor in Hematopoietic Cell Transplantation for Severe Aplastic Anemia SungNam Lim, Je-Hwan Lee, MD, PhD,

Hematopoietic Stem Cell Transplantation in Australia and New Zealand,

Outcomes among Patients with Recurrent High-Risk Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation Marco Mielcarek, Barry.

Mary Eapen Biology of Blood and Marrow Transplantation

Futility of Relapsed Diffuse Large B Cell Lymphoma Transplantation?

Presentation transcript:

The Effect of Folinic Acid on Methylenetetrahydrofolate Reductase Polymorphisms in Methotrexate-Treated Allogeneic Hematopoietic Stem Cell Transplants Nicholas M. Murphy, Mary Diviney, Jeff Szer, Peter Bardy, Andrew Grigg, Rosemary Hoyt, Belinda King-Kallimanis, Rhonda Holdsworth, James McCluskey, Brian D. Tait Biology of Blood and Marrow Transplantation Volume 18, Issue 5, Pages 722-730 (May 2012) DOI: 10.1016/j.bbmt.2011.09.001 Copyright © 2012 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 1 The hazard/odds ratio of clinical outcomes influenced by the donor MTHFR 677 genotypes. (A) Patients not provided with FA rescue; (B) patients provided with FA rescue; (C) Kaplan-Meier graph of the first day that a manifestation of GVHD was observed; (D) Kaplan-Meier graph of the incidence of survival following transplantation. Significant associations are indicated by the hazard/odds ratio and its respective confidence interval both <1 for a lower risk of events occurring or >1 for a higher risk of events occurring. Biology of Blood and Marrow Transplantation 2012 18, 722-730DOI: (10.1016/j.bbmt.2011.09.001) Copyright © 2012 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 2 The hazard/odds ratio of clinical outcomes influenced by the patient MTHFR 677 genotypes. (A) Patients not provided with FA rescue; (B) patients provided with FA rescue; (C) Kaplan-Meier graph of the first day that a manifestation of GVHD was observed; (D) Kaplan-Meier graph of the incidence of survival following transplantation. Significant associations are indicated by the hazard/odds ratio and its respective confidence interval both <1 for a lower risk of events occurring or >1 for a higher risk of events occurring. Biology of Blood and Marrow Transplantation 2012 18, 722-730DOI: (10.1016/j.bbmt.2011.09.001) Copyright © 2012 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 3 The hazard/odds ratio of clinical outcomes influenced by the donor MTHFR 1298 genotypes. (A) Patients not provided with FA rescue; (B) patients provided with FA rescue; (C) Kaplan-Meier plot of EFS; (D) Kaplan-Meier plot of overall survival following transplantation. Significant associations are indicated by the hazard/odds ratio and its respective confidence interval both <1 for a lower risk of events occurring or >1 for a higher risk of events occurring. Biology of Blood and Marrow Transplantation 2012 18, 722-730DOI: (10.1016/j.bbmt.2011.09.001) Copyright © 2012 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 4 The hazard/odds ratio of clinical outcomes influenced by the patient MTHFR 1298 genotypes. (A) Patients not provided with FA rescue; (B) patients provided with FA rescue; (C) Kaplan-Meier graph of the incidence of opiate use; (D) Kaplan-Meier plot of the incidence of total parenteral nutrition use. Significant associations are indicated by the hazard/odds ratio and its respective confidence interval both <1 for a lower risk of events occurring or >1 for a higher risk of events occurring. Biology of Blood and Marrow Transplantation 2012 18, 722-730DOI: (10.1016/j.bbmt.2011.09.001) Copyright © 2012 American Society for Blood and Marrow Transplantation Terms and Conditions